Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2014

View Archived Issues

Novel association found for intracranial aneurysm susceptibility

Cardioxyl Pharmaceuticals begins first trial of CXL-1427

Roche discloses novel protein ligase inhibitors for cancer

Daiichi Sankyo discloses new agents for bacterial infections

Novel thrombin inhibitors prepared at Merck & Co.

Emory University patents new NMDA receptor modulators

Amgen divulges novel TRPM8 antagonists for migraine

Long-term analysis of a prognostic gene signature for breast cancer

NICE publishes final guidance recommending Eylea in England

Known cognition enhancer active in models of neuropathic pain

Application for approval of an oral disintegrating tablet formulation

Critical Outcome Technologies signs letter of intent with Portage Biotech for COTI-2

Treatment under way in phase IIb study of brilacidin for ABSSSI

Orexigen Therapeutics receives European CHMP questions on NB-32 MAA

Bexsero available in Canada

NICE final guidance recommends Pixuvri for relapsed/refractory B-cell NHL

Phase I study of tuberculosis vaccine DAR-901 opens

Dosing completed in phase II trial of Zoenasa for ulcerative colitis

Multifunctional polynitroxylated albumin for the early treatment of stroke

Chinese researchers synthesize new PI3Kdelta inhibitors

CytoVac initiates phase II study of ALECSAT for glioblastoma multiforme

InDex Pharmaceuticals closes new rights issue

NeRRe Therapeutics initiates phase II study of orvepitant for EGFR inhibitor-induced pruritus

Mast Therapeutics opens international enrollment in EPIC study of MST-188

Adocia reports preliminary results from phase I/II trial of BioChaperone Combo

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...